AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31252655
Drug: Caffeine 6
RxNorm normalized name: caffeine 65 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 6 mg/kg/b.m. (CAF‐6)
Trial: 31252655
Drug: Caffeine 9
RxNorm normalized name: multivit,calcium,min/ferrous fum/folic acid/guarana/caffeine 9 mg iron-400 mcg-200 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 9 mg/kg/b.m. (CAF‐9)
Trial: 27007392
Drug: Control (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (4 g olive oil)
Trial: 10378852
Drug: Nitroglycerin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin infusion (0.5 to 1 microg/kg/min)
Trial: 8710426
Drug: Dexfenfluramine treatment
RxNorm normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexfenfluramine treatment with a low calorie diet
Trial: 8710426
Drug: Dexfenfluramine treatment
RxNorm normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexfenfluramine treatment
Trial: 2039811
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg bumetanide
Trial: 7014105
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg xipamide
Trial: 23842536
Drug: Intranasal ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal ketamine (1 mg/kg)
Trial: 29525821
Drug: Atorvastatin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (2 loading doses of 80 mg before and 24 hours after PCI)
Trial: 30640985
Drug: Xingfeng Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xingfeng Capsule (XFC), 3 pills each time, three times per day for 3 months
Trial: 22258265
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D (100,000 IU cholecalciferol given every 2 months) and calcium (1 g/d)
Trial: 20073463
Drug: Berry group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berry group (160 g/day of bilberries, lingonberries, black currants, and chokeberries)
Trial: 16226521
Drug: Intravitreal injections
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injections of 4 mg triamcinolone acetonide (TA)
Trial: 16226521
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of 4 mg TA followed by MLG
Trial: 12107236
Drug: Acipimox (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (250 mg, orally, three times daily)
Trial: 11772142
Drug: Rabeprazole 20
RxNorm normalized name: RABEprazole 20 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 20 mg/day or 10 mg twice daily
Trial: 12421488
Drug: Rabeprazole 10
RxNorm normalized name: RABEprazole 10 mg oral delayed release tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole 10 mg/day
Trial: 11772142
Drug: Rabeprazole plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole plus clarithromycin and amoxicillin
Trial: 7735957
Drug: Comparison with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison with complete murine monoclonal anti-TNF alpha-antibody
Trial: 26551066
Drug: Sodium hyaluronate
RxNorm normalized name: sodium hyaluronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium hyaluronate (Viscoseal) 10 mL intra-articularly
Trial: 26551066
Drug: Bupivacaine 10
RxNorm normalized name: BUPivacaine 100 mg parenteral implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 10 mL intra-articularly
Trial: 17200358
Drug: Epirubicin 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 100 mg/m² and Cyclophosphamide 600 mg/m² (EC) every 10 to 11 days for four cycles followed by Paclitaxel 175 mg/m² every 10 to 11 days for four cycles with filgrastim support (300 microg s.c. daily) from day 2 to 24 hours before the next treatment
Trial: 6281293
Drug: MK 421
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK 421 (20 mg orally, twice daily)
Trial: 31362715
Drug: Six-month ART
RxNorm normalized name: moth bean extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six-month ART refill in Intervention ACs, meeting twice annually.
Trial: 30594153
Drug: Arm A
RxNorm normalized name: Warm antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm A (perioperative arm): 2 cycles nab‐paclitaxel (125 mg/m2)/gemcitabine (1000 mg/m2, d1, 8 and 15 of a 28 day‐cycle) followed by tumor surgery followed by 4 cycles nab‐paclitaxel/gemcitabine
Trial: 24518280
Drug: LYM-X-SORB™ (LXS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYM-X-SORB™ (LXS) dietary supplements
Trial: 24518280
Drug: Placebo dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dietary supplements
Trial: 22997994
Drug: Extensive antiarrhythmic
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extensive antiarrhythmic drugs (AADs) therapy (class Ic and III AADs)
Trial: 22997994
Drug: One AAD
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One AAD therapy (class Ic or III AADs alone)
Trial: 20678685
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (new generic losartan potassium 50-mg tablet)
Trial: 20678685
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (branded losartan potassium 50-mg tablet)
Trial: 17127027
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation
Trial: 10758775
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation
Trial: 394267
Drug: Caerulein (ceruletide)
RxNorm normalized name: Passiflora caerulea fruit extract
DrugBank: Ceruletide (DB00403)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caerulein (ceruletide) 0.3 mcg/kg intravenously every 4 hours
Trial: 31296289
Drug: Higher-dose edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose edoxaban
Trial: 30462220
Drug: Lower-dose edoxaban
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose edoxaban
Trial: 25222386
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy plus CABG (610 patients)
Trial: 25222386
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy alone (602 patients)
Trial: 11957164
Drug: Methylprednisolone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (15 mg/kg intravenously 1 hour before surgery and 0.3 mg/kg intravenously every 6 hours for 4 doses)
Trial: 10410529
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for pancreatic endocrine tumors
Trial: 7586430
Drug: Glyceryl trinitrate-verapamil
RxNorm normalized name: glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glyceryl trinitrate-verapamil (GV) solution
Trial: 7586430
Drug: Ringer's solution
RxNorm normalized name: Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's solution (untreated)
Trial: 7389482
Drug: Taurolin (new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurolin (new chemotherapeutic agent)
Trial: 7017311
Drug: Conventional antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antibiotic therapy
Trial: 26337448
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of red wine grape pomace flour (WGPF) per day
Trial: 23295262
Drug: Intanza 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intanza 15 μg intradermal vaccine
Trial: 23295262
Drug: Inflexal V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inflexal V virosomal adjuvanted intramuscular vaccine
Trial: 19366849
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (IIT) with glycemia target of 80-110 mg/dl
Trial: 19366849
Drug: Conventional insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional insulin therapy (CIT) with glycemia target above 215 mg/dl
Trial: 16357619
Drug: Nadolol plus
RxNorm normalized name: Nadolol
DrugBank: Nadolol (DB01203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nadolol plus isosorbide mononitrate (medication group)
Trial: 16357619
Drug: Endoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic treatment (sclerotherapy or ligation) (control group)
Trial: 8129382
Drug: Hyperthermia combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthermia combined with irradiation and chemotherapy (HCR)
Trial: 8129382
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and radiotherapy (CR)
Trial: 8129382
Drug: Hyperthermia combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperthermia combined with irradiation and chemotherapy (HCR) with cisplatin
Trial: 8129382
Drug: Multi-drug combined
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-drug combined treatment from other institutes
Trial: 2656902
Drug: Felodipine extended
RxNorm normalized name: Felodipine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine extended release (10 mg)
Trial: 26595963
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with yellow turpentine bathtubs and bronchodilators inhalations (atrovent inhalations).
Trial: 26595963
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with yellow turpentine bathtubs alone.
Trial: 26595963
Drug: Therapeutic physical
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic physical exercises and symptomatic medications (control group).
Trial: 23887469
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (Control group, n=17)
Trial: 21912335
Drug: Sleep-inducing medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep-inducing medication (specific agents not detailed), administered over a 2-week period.
Trial: 21912335
Drug: Polysomnography (PSG)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polysomnography (PSG) monitoring conducted for three consecutive nights each week, without medication on the first night as a baseline.
Trial: 17301824
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg/daily)
Trial: 12825849
Drug: Menopausal status,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menopausal status, prior hormone replacement therapy, and estrogen/progesterone receptor status of the breast tumors
Trial: 8673189
Drug: Intramuscular ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ketamine (KET) 4 mg/kg with atropine sulfate 0.01 mg/kg
Trial: 1883251
Drug: Nalmefene (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalmefene (2.5 mg oral dose)
Trial: 3935120
Drug: Chlorpropamide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpropamide (250 mg)
Trial: 6416476
Drug: Insulin dependent
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin dependent diabetics
Trial: 27555374
Drug: Prophylactic oral
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic oral and maxillofacial treatment with 3-monthly dental follow-ups
Trial: 15374729
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of finasteride every day
Trial: 15374729
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of finasteride every 3 days
Trial: 19932356
Drug: Salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 50 microg twice a day
Trial: 2684175
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract EGb 761 (120 mg daily dose, 40 mg administered 3 times daily for 8 weeks)
Trial: 28606441
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D therapy (50,000 IU of vitamin D3 intramuscularly monthly for six months)
Trial: 28606441
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (distilled water, 0.25mL monthly for six months)
Trial: 19894383
Drug: Compound Zhebei
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Zhebei Granules (CZG)
Trial: 16380311
Drug: Psychic healing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychic healing treatment (exact dosage and duration not specified)
Trial: 16380311
Drug: Both treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatment and control groups (belief in psychic healing)
Trial: 3698066
Drug: Ketoprofen 100
RxNorm normalized name: ketoprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100 mg TID
Trial: 30351342
Drug: Daily Intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Intake Guide (FoPL)
Trial: 27538776
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose intraoperative electron radiotherapy (IOERT)
Trial: 24696094
Drug: Bitopertin 30
RxNorm normalized name: Bitopertin
DrugBank: Bitopertin (DB12426)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bitopertin 30 mg/d
Trial: 17020438
Drug: Pregabalin (150-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (150-600 mg)
Trial: 12017347
Drug: Oral eletriptan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral eletriptan (1.5-30 mg or 30-120 mg)
Trial: 12017347
Drug: Intravenous eletriptan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous eletriptan (1.67-50 microg/kg or 50-102 microg/kg)
Trial: 12017347
Drug: Oral eletriptan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral eletriptan doses > or = 60 mg
Trial: 2182732
Drug: Single-dose trimethoprim
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose trimethoprim treatment
Trial: 28610561
Drug: Blended care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended care (Act and Feel treatment: an eight-week web-based program based on behavioral activation with integrated monitoring of depressive symptomatology and automatized feedback)
Trial: 7685221
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin (activated clotting time, > 180 sec)
Trial: 3319461
Drug: 5-ASA suppositories,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-ASA suppositories, 500 mg t.i.d. for 6 weeks
Trial: 31320446
Drug: Liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.8 mg daily
Trial: 16162943
Drug: 25 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g/day spread containing 2.0 g of plant sterols
Trial: 16162943
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment consisting of 25 g/day control spread
Trial: 10319771
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline infusion (30 ml x kg(‐1) x h(‐1))
Trial: 31816446
Drug: Ustekinumab (130
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab (130 mg intravenous induction)
Trial: 31816446
Drug: Ustekinumab (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab (90 mg subcutaneous maintenance every 8 weeks)
Trial: 28372596
Drug: Ketamine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.8 mg/kg administered intravenously over 40 minutes) plus manualised psychological therapy
Trial: 28372596
Drug: Ketamine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.8 mg/kg administered intravenously over 40 minutes) plus alcohol education control
Trial: 20970888
Drug: 0.03 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg/kg IV midazolam
Trial: 20084738
Drug: SC Johnson's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC Johnson's Autan Bayrepel Lotion
Trial: 22968615
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with antibiotics
Trial: 8124045
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clindamycin with sulfamethoxydiazine and/or pyrimethamine
Trial: 8124045
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with clindamycin alone
Trial: 8124045
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clindamycin and pyrimethamine
Trial: 2887327
Drug: Flumazenil (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (up to 1 mg, intravenous administration)
Trial: 29970059
Drug: 70 mg
RxNorm normalized name: silybin 70 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg of alendronate sodium and 5600 IU of vitamin D3 (ALN/D5600)
Trial: 29970059
Drug: Calcitriol (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcitriol (0.25 μg daily)
Trial: 28400148
Drug: Topical betulin
RxNorm normalized name: betulin
DrugBank: Betulin (DB16890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical betulin gel (TBG) consisting of 10% birch bark extract and 90% sunflower oil
Trial: 26270686
Drug: Micafungin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin (100 mg/d)
Trial: 24041914
Drug: Intravenous 0.5
RxNorm normalized name: immune globulin intravenous 0.5 g intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 0.5 ml Optison
Trial: 24041914
Drug: Intravenous 0.5
RxNorm normalized name: immune globulin intravenous 0.5 g intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 0.5 ml placebo (5% dextrose)
Trial: 11899644
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with hematopoietic stem-cell transplantation (HDC/HSCT)
Trial: 1388643
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desipramine (DMI) at 150 mg daily
Trial: 1388643
Drug: Cocaine doses
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine doses (0.125 to 0.5 mg/kg)
Trial: 24090124
Drug: Steel infusion
RxNorm normalized name: TruSteel Infusion Set 6MM-23 inch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steel infusion set
Trial: 22527351
Drug: Lersivirine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lersivirine 1,000 mg QD with midazolam
Trial: 22527351
Drug: Lersivirine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lersivirine 1,000 mg QD with oral contraceptives (ethinylestradiol and levonorgestrel)
Trial: 20113698
Drug: Sesame oil
RxNorm normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sesame oil (oral administration)
Trial: 17684125
Drug: 201L allele
RxNorm normalized name: Human Factor XIII (A2) homodimer (allele F13A*1B), recombinant DNA origin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 201L allele of S201L (TC versus CC)
Trial: 16275814
Drug: Methylphenidate hydrochloride
RxNorm normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylphenidate hydrochloride (low, medium, and high doses ranging from 7.5 mg/d to 50.0 mg/d)
Trial: 10617523
Drug: Problem solving
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem solving treatment
Trial: 30905242
Drug: 1.1% NaF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1% NaF brush-on gel used at bedtime in combination with 0.22% NaF dentifrice 2 times/day
Trial: 19834016
Drug: Tight control
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight control (target 70 to 110 mg/dL)
Trial: 19834016
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (target 70 to 300 mg/dL)
Trial: 12067330
Drug: IgM anti-GM1
RxNorm normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IgM anti-GM1 antibodies in patients with PD (detection via ELISA, initial dilution 1:800, positive at absorbance > 0.05)